About the Conference
The conference brings together experts and thought leaders from around the world to discuss the mechanism of toxicities and symptom burden after hematopoietic cell transplantation (HCT) and cellular and gene therapies; current advances in the field; and best practices to both prevent and treat these toxicities and symptoms.
The program will include a wide range of pre-clinical, translational and clinical topics, will offer networking opportunities and a dedicated poster reception showcasing research in toxicities. This conference will be offered in-person and virtually.
Abstracts
ASTCT is currently accepting abstracts for the Toxicities Conference, giving you the opportunity to present your research to a broad audience. We welcome abstract submissions from fellows, residents, nurses, APPs, pharmacists, and physicians. The top five best abstracts will receive complimentary registration to the conference. The abstract submission window will close on Sunday, September 8 at 11:00 p.m. CT.
Submit Abstract
Abstract Submission Criteria
Abstracts will be scored based on the following criteria:
- Importance and Relevance: Is a clear rationale for the work provided? Does the study address an important question? Do its findings have the potential to advance the field of blood and marrow or cellular therapies?
- Originality and Innovation: Is the work novel? Does it present new findings and/or address a problem using an original or improved approach?
- Quality of Methods and Writing: Are methods well described and valid to answer the question? Is the abstract clear and well written? Is the abstract within the 300-word limit?
Please note that the abstract submission form does not have a tracker for word count. We recommend that you prepare your abstract submission in a Word document to confirm that you stay within the 300-word limit.
The top five abstracts will receive complimentary registration to the meeting. All accepted abstracts will be required to present their posters at the conference during the poster reception on Friday, November 15.
Responsibility of Abstract Authors
The Presenting Author is responsible for the following:
- Ensuring that all authors have read the abstract and agreed to be co-authors.
- Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by the 4th International Conference on Toxicities of Transplantation and Cellular Therapies.
- Obtaining all of the conflict-of-interest disclosure information from co-authors.
- Making certain that abstracts are complete (tables included and labeled) and written in clear, concise and grammatically correct English, so that reviewers are able to focus solely on the scientific merits of the submission. For authors with any questions regarding the clarity, grammar or spelling of their abstract, we encourage identifying and using an independent reviewer to edit the abstract prior to submission.
If you are also considering submitting your abstract to the 2025 Tandem Meetings of ASTCT and CIBMTR, you can do so, but please review the restrictions below:
- You will not be considered for a best abstract award (both in the scientific categories and tracks). The title and author information will be disclosed to the SOC Co-Chairs and the track planners (if applicable).
- You cannot be published elsewhere.
Please contact Haedyn Smith with any questions regarding your submission.
Who Should Attend
Physicians, advanced practice providers, and nurses who treat or refer patients for HCT or immune effector cell therapies.
Key Information
Topics include:
- Acute, late, and potentially underrepresented toxicities of transplantation, CAR T, and gene therapies.
- Enhancing health resilience and well-being in our transplantation and cellular therapy patients through nutrition, exercise science, and integrative medicine.
- Novel approaches to improve the outcomes of transplantation and CAR T therapy in older patients.
- New approaches incorporating machine learning for prediction and detection of toxicities to allow for earlier intervention.
- Understanding the interaction between the choice GVHD prophylaxis and toxicities after allo-HCT in the era of PTCy.
- Unique toxicity considerations in patients receiving cellular therapies for solid organ malignancies.
Registration
Registration rates for the in-person and virtual conference are the same.
Register
| Registration Rates |
| Type |
Price |
| Residents of low and low middle income countries |
$15 |
| Member Rate |
$400 |
| Trainee Rate |
$350 |
| Non-Member Registration + Membership Bundle (MD/PhD) |
$675 |
| Non-Member Registration + Affiliate Membership Bundle (Non MD/PhD) |
$575 |
| Non-Member Rate |
$725 |
| Industry Rate |
$850 |
Agenda
Day 1: Friday, November 15
| 6:30 AM |
Registration Open |
| 7:30 – 8:15 AM |
Breakfast Product Theater |
| 8:15 AM |
Introduction and Welcome Remarks |
|
8:15 – 9:15 AM
|
Keynote Lecture: What is Host Resilience, and Does it Matter?
Mina Sedrak, MD, MS; UCLA Health
Organizing Committee Session Chair:
Sergio Giralt, MD; Memorial Sloan Kettering Cancer Center
|
| 9:15 - 10:55 AM |
Main Session 1: The Expanding Scope of Toxicities after Transplantation and Cellular and Gene Therapies
Susan Prockop, MD; Boston Children’s
Organizing Committee Session Chair:
Christina Cho, MD; Hackensack University Medical Center
|
|
Gene Therapy in Pediatrics and Young Adults: Challenges, Opportunities, and Safety Considerations
Susan Prockop, MD; Boston Children’s
|
|
Biological Correlates of Psychosocial Toxicities
Lena Winestone, MD; UCSF Benioff Children's Hospitals
|
|
Allogeneic Transplant in SCD Patients with ESRD
Alexandra Gomez-Arteaga, MD; Weill Cornell Medicine
|
|
Toxicities of Gene Therapies for Sickle Cell Disease
Alexis Leonard, MD; St. Jude’s
|
| Panel Discussion; Q&A |
| 10:55 – 11:10 AM |
Break |
|
11:10 - 12:50 PM
|
Main Session 2: Optimizing Host Resilience
Saro Armenian, DO, MPH; City of Hope
Organizing Committee Session Chair:
Sergio Giralt, MD; Memorial Sloan Kettering Cancer Center
|
Phenotyping and Risk Characterization Prior to HCT and Cellular Therapy
Saro Armenian, DO, MPH; City of Hope |
|
Delivery of Multidisciplinary Care Prior to and During HCT and Cellular Therapy
Reena Jayani, MD; Vanderbilt University
|
|
Unique Considerations for the Outpatient HCT and Cellular Therapy Setting
Othman Akhtar, MD; Medical College of Wisconsin
|
Exercise Based Interventions in Survivors to Restore Resilience
Kirsten Ness, PT, PhD, FAPTA; St. Jude’s |
| Panel Discussion; Q&A |
| 12:50 – 1:50 PM |
Lunch Break and Lunch Product Theater |
| 1:50 - 3:30 PM |
Main Session 3: Treating Older Transplantation and Cellular Therapy Recipients
Mariam Nawas, MD; University of Chicago Medicine
Organizing Committee Session Chair:
Michael Scordo, MD; Memorial Sloan Kettering Cancer Center |
|
Older Patients, New Approaches: Novel and Reduced Toxicity Conditioning Regimen Alternatives to Improve Outcomes
Uday Popat, MD; MD Anderson Cancer Center
|
Using Risk Stratification Tools to Optimize and Personalize HCT in Older Adults
Shannon McCurdy, MD; University of Pennsylvania |
|
Biomarkers as Measures of Fitness in HCT Recipients
Ashley Rosko, MD; The Ohio State Comprehensive Cancer Center
|
Frailty and CAR-T: What Does it Mean to be CAR-T Eligible?
Mariam Nawas, MD; University of Chicago Medicine |
| Panel Discussion; Q&A |
| 3:30 – 3:45 PM |
Break |
| 3:45 - 5:25 PM |
Main Session 4: Promises and Pitfalls of Emerging Technologies
Roni Shouval, MD, PhD; Memorial Sloan Kettering Cancer Center
Organizing Committee Session Chair:
William Wood, MD, MPH; University of North Carolina at Chapel Hill |
Remote Monitoring of CAR T Patients
Yi Lin, MD, PhD; Mayo Clinic |
Patient-reported Outcomes in Cellular Therapy
Rachel Cusatis, PhD; Medical College of Wisconsin |
Remote Management of Oncological Patients
Sarah Wall, MD, MPH; The Ohio State Comprehensive Cancer Center |
Multimodal Machine Learning for Toxicity Prediction in CAR T
Roni Shouval, MD, PhD; Memorial Sloan Kettering Cancer Center |
| Panel Discussion; Q&A |
| 5:25 – 7:00 PM |
Networking and Poster Reception |
Day 2: Saturday, November 16
| 7:30 – 8:15 AM |
Breakfast Product Theater |
| 8:15 AM |
Day 2 Welcome |
| 8:15 - 9:15 AM |
Morning Debate: Toxicities in the Era of PTCy: Are Novel Combinations as Effective as PTCy?
Brian Shaffer, MD; Memorial Sloan Kettering Cancer Center
Organizing Committee Session Chair:
Shernan Holtan, MD; Roswell Park Comprehensive Cancer Center |
|
Should the dose of PTCy be reduced?
Samer al-Homsi, MD; Northwell Health
|
|
Obinutuzumab Study
Mahasweta Gooptu, MD; Dana-Farber Cancer Institute
|
|
Toxicity Focus
Betty Hamilton, MD; Cleveland Clinic
|
| 9:15 – 9:30 AM |
Break |
| 9:30 - 11:10 AM |
Main Session 5: Toxicities of Cellular Therapies for Solid Organ Malignancies
Alison Betof Warner, MD, PhD; Stanford Medicine
Organizing Committee Session Chair: Melody Smith, MD; Stanford Medicine |
Head and Neck Cancers
Kedar Kirtane, MD; Moffitt Cancer Center |
CAR T-cells for GBM
Reena Thomas, MD, PhD; Stanford Medicine |
TIL Therapy for Melanoma and Beyond: Management and Toxicities
Allison Betof Warner, MD, PhD; Stanford Medicine |
| Panel Discussion; Q&A |
| 11:10 - 11:25 AM |
Break |
| 11:25 – 12:25 PM |
Keynote Lecture: Looking Back, Looking Forward
Mohamed Sorror, MD, MSc; Fred Hutchinson Cancer Center |
| 12:25 PM |
Closing Remarks and Adjourn |
Housing
The Notary Hotel, Philadelphia, Autograph Collection
21 N Juniper Street
Philadelphia, PA 19107
(215) 496-3200
Registered attendees will receive the housing link to secure discounted room rates in their official registration confirmation email.
Room Rate
$259 plus any applicable taxes and fees (single/double).
Housing Rate Cutoff
To take advantage of the discounted room rate, be sure to book your reservation on or before October 24, 2024. After October 24, the room block will be released and the negotiated room rates may not be available. Please make sure the hotel is aware of any special needs. They will assign specific room types and any other requests based on availability.
Deposits
Please have your credit card information on hand upon booking your reservation. The Notary Hotel requires each individual reservation be guaranteed with a deposit equal to one night's room and tax.
Changes or Cancellations
The Notary Hotel requires that you cancel your reservation (72) hours prior to your arrival. The deposit of one night's room and tax will be forfeited for cancellations made less than (72) hours from arrival. Please call the hotel directly to make a cancellation and keep your cancellation confirmation number for your records.
Confirmations
The hotel will send you a confirmation to the email used in booking your reservation using the customized online reservation link provided by ASTCT. Review it carefully for accuracy and keep a copy for your records.
Support
Contact Angie Dahl, Director of Development, to learn more about sponsorship opportunities. Review the Toxicities Conference prospectus.